ArticleDiscover oncology2025
Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Sequential immune checkpoint inhibition after palliative radiotherapy in patients with advanced head and neck squamous cell carcinoma: A retrospective cohort study.Molecular and clinical oncology · 2026Article
- Prognostic modeling and validation of middle ear malignancy outcomes on the basis of SEER population data.Translational cancer research · 2026Article
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Complete response of a giant metastatic neck mass in tonsillar squamous cell carcinoma achieved with radiotherapy combined with immunotherapy: a case report.Frontiers in oncology · 2026Article
- Preoperative Systemic Inflammation Response Index Predicts Survival Outcome for Previously Irradiated Metachronous Secondary Head and Neck Cancer Patients.Cancer management and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIt is uncertain whether the combination of immunotherapy and radiotherapy can provide survival benefits for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
methodsWe retrospectively analyzed the impact of radiotherapy on the efficacy of immunotherapy and prognostic analysis in 113 patients with R/M HNSCC in our institution from 2018 to 2022. The Kaplan-Meier method was utilized for survival analysis, and Cox regression analysis was conducted to identify prognostic factors.
resultsThe median follow-up time was 14.0 months. During immunotherapy, 37 patients received radiotherapy, targeting primary tumors, lymph nodes, metastasis in liver, lung, bone, and other sites. We found that the group receiving immunotherapy combined with radiotherapy had higher objective response rate (67.6% vs 39.5%, p = 0.009) and disease control rate (94.6% vs 61.8%, p = 0.001) than those without radiotherapy. The median progression-free survival (20.0 months vs 4.0 months, p = 0.00098) and overall survival (not reached vs 26.0 months, p = 0.006) were improved in patients receiving radiotherapy compared to those not.
conclusionsThe combination of immunotherapy and radiotherapy demonstrates improved clinical outcomes in R/M HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.